JP2016526571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526571A5 JP2016526571A5 JP2016525409A JP2016525409A JP2016526571A5 JP 2016526571 A5 JP2016526571 A5 JP 2016526571A5 JP 2016525409 A JP2016525409 A JP 2016525409A JP 2016525409 A JP2016525409 A JP 2016525409A JP 2016526571 A5 JP2016526571 A5 JP 2016526571A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- acceptable salt
- pharmaceutically acceptable
- pain
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 136
- 150000003839 salts Chemical class 0.000 claims description 80
- 208000002193 Pain Diseases 0.000 claims description 69
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 230000001154 acute effect Effects 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
- 208000004296 neuralgia Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- -1 fluoro-C1-C6 alkoxy Chemical group 0.000 claims description 10
- 208000008035 Back Pain Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 208000006561 Cluster Headache Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 206010028836 Neck pain Diseases 0.000 claims description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 5
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 108010052164 Sodium Channels Proteins 0.000 claims description 4
- 102000018674 Sodium Channels Human genes 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- 229930192474 thiophene Chemical group 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 208000000003 Breakthrough pain Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000004404 Intractable Pain Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 206010033557 Palpitations Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000005176 gastrointestinal motility Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 206010031009 Oral pain Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000025609 Urogenital disease Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 201000000182 femoral cancer Diseases 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844499P | 2013-07-10 | 2013-07-10 | |
| US61/844,499 | 2013-07-10 | ||
| PCT/US2014/045675 WO2015006280A1 (en) | 2013-07-10 | 2014-07-08 | Fused piperidine amides as modulators of ion channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526571A JP2016526571A (ja) | 2016-09-05 |
| JP2016526571A5 true JP2016526571A5 (cg-RX-API-DMAC7.html) | 2017-08-17 |
| JP6605462B2 JP6605462B2 (ja) | 2019-11-13 |
Family
ID=51230209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525409A Active JP6605462B2 (ja) | 2013-07-10 | 2014-07-08 | イオンチャネルのモジュレーターとしての縮合ピペリジンアミド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10233191B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3019478B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6605462B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102306951B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105473554B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014287471C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2917198C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2780699T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL243495B (cg-RX-API-DMAC7.html) |
| MX (1) | MX368728B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2741810C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201600082VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015006280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891313A1 (ru) | 2015-12-18 | 2018-11-30 | Мерк Шарп И Доум Корп. | Замещенные гидроксиалкиламинами и гидроксициклоалкиламинами соединения диаминарилсульфонамидов с избирательной активностью в потенциалзависимых натриевых каналах |
| KR102079844B1 (ko) * | 2016-09-20 | 2020-02-20 | 가톨릭대학교 산학협력단 | 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물 |
| JP6890179B2 (ja) * | 2016-12-02 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式アミド化合物及びその使用方法 |
| CN110291383B (zh) * | 2017-02-23 | 2021-12-28 | 株式会社Ihi | Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法 |
| AU2018300043B2 (en) | 2017-07-14 | 2021-04-01 | F. Hoffmann-La Roche Ag | Bicyclic ketone compounds and methods of use thereof |
| CN109574927A (zh) * | 2017-09-29 | 2019-04-05 | 浙江海正药业股份有限公司 | N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途 |
| MA50503A (fr) | 2017-10-31 | 2020-09-09 | Hoffmann La Roche | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés |
| KR102812440B1 (ko) * | 2018-09-10 | 2025-05-26 | 가껭세이야꾸가부시기가이샤 | 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제 |
| TW202043229A (zh) | 2019-01-11 | 2020-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環酮化合物及其使用方法 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| AR131658A1 (es) | 2023-01-30 | 2025-04-16 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits |
| EP4660184A1 (en) | 2023-01-30 | 2025-12-10 | Eurofarma Laboratórios S.A. | Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits |
| AR131690A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| WO2024159285A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| CN119285621B (zh) * | 2024-12-13 | 2025-07-18 | 嘉兴安帝康生物科技有限公司 | 作为钠通道调节剂的四氢呋喃甲酰胺类化合物及其在医药上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549641A (en) * | 1966-06-28 | 1970-12-22 | Warner Lambert Pharmaceutical | Pyrano pyridines and process for their production |
| SE7509022L (sv) | 1974-09-09 | 1976-03-10 | Du Pont | Foreningar med analgetisk verkan |
| US4301290A (en) * | 1975-12-16 | 1981-11-17 | Sandoz Ltd. | Organic compounds |
| DE2655150A1 (de) | 1975-12-16 | 1977-06-23 | Sandoz Ag | Neue organische verbindungen, ihre herstellung und verwendung |
| BG30927A3 (bg) * | 1977-12-27 | 1981-09-15 | Eli Lilly And Company | Метод за получаване на транс-4-алфа-фенил-октахидро-1н-2 пиридини |
| DE2907461A1 (de) * | 1978-03-10 | 1979-09-20 | Sandoz Ag | Isochinolinderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| DE4427648A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
| DE4341402A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
| JP2003327534A (ja) * | 1999-11-30 | 2003-11-19 | Toray Ind Inc | 頻尿若しくは尿失禁の治療又は予防剤 |
| RU2006106710A (ru) * | 2003-08-05 | 2007-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Конденсированные пиримидиновые соединения в качестве ингибиторов потенциалозависимых ионных каналов |
| WO2008130319A2 (en) * | 2007-04-23 | 2008-10-30 | Astrazeneca Ab | Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain |
| WO2009005459A1 (en) * | 2007-06-29 | 2009-01-08 | Astrazeneca Ab | Phenyl-1,2, 3,4-tetrahydroisoquinolinone derivatives and their use in the treatment of a pain disorder |
| WO2010151595A1 (en) * | 2009-06-26 | 2010-12-29 | Schering Corporation | Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers |
| WO2011050200A1 (en) * | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| PL2670752T3 (pl) * | 2011-02-02 | 2016-09-30 | Pirolopirazynowe spirocykliczne piperydynoamidy jako modulatory kanałów jonowych |
-
2014
- 2014-07-08 CA CA2917198A patent/CA2917198C/en active Active
- 2014-07-08 US US14/903,475 patent/US10233191B2/en active Active
- 2014-07-08 EP EP14744707.2A patent/EP3019478B1/en active Active
- 2014-07-08 ES ES14744707T patent/ES2780699T3/es active Active
- 2014-07-08 KR KR1020167003469A patent/KR102306951B1/ko active Active
- 2014-07-08 WO PCT/US2014/045675 patent/WO2015006280A1/en not_active Ceased
- 2014-07-08 RU RU2016104080A patent/RU2741810C2/ru active
- 2014-07-08 MX MX2016000038A patent/MX368728B/es active IP Right Grant
- 2014-07-08 JP JP2016525409A patent/JP6605462B2/ja active Active
- 2014-07-08 CN CN201480045419.7A patent/CN105473554B/zh active Active
- 2014-07-08 AU AU2014287471A patent/AU2014287471C1/en active Active
- 2014-07-08 SG SG11201600082VA patent/SG11201600082VA/en unknown
-
2016
- 2016-01-07 IL IL243495A patent/IL243495B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526571A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508169A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508756A5 (cg-RX-API-DMAC7.html) | ||
| JP2014504642A5 (cg-RX-API-DMAC7.html) | ||
| RU2563030C2 (ru) | Сульфонамидные соединения, обладающие антагонистической активностью в отношении trpm8 | |
| JP6866967B2 (ja) | サイクリン依存性キナーゼｃｄｋ９の新規阻害剤 | |
| RU2016151727A (ru) | Нейроактивные стероиды, композиции и их применения | |
| CA2739739C (en) | Sulfoximine-substituted anilino-pyrimidine derivatives as cdk inhibitors, production and use thereof as medicinal products | |
| RU2506261C2 (ru) | Производные хиназолина | |
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| JP2007520504A5 (cg-RX-API-DMAC7.html) | ||
| ES2824801T3 (es) | Sal de compuesto heterocíclico sustituido con halógeno | |
| KR20100016076A (ko) | 신규 피롤리논 유도체 및 그것을 함유하는 의약 조성물 | |
| EP4196228A1 (en) | N-cyclyl-sulfonamides useful for inhibiting raf | |
| JP7675020B2 (ja) | Ｂａｘ阻害剤およびその使用 | |
| CN102134218A (zh) | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 | |
| CA3191829A1 (en) | Cd73 inhibitor and application thereof in medicine | |
| JP2020534373A (ja) | キナーゼ阻害剤としての環状イミノピリミジン誘導体 | |
| CN114349738A (zh) | 一类靶向降解cdk2的小分子缀合物及其应用 | |
| KR20200073265A (ko) | 함질소 6원환 화합물 | |
| DE102009015070A1 (de) | Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel | |
| RU2005135850A (ru) | Замещенные изохромановые соединения для лечения метаболических расстройств, рака и другие заболеваний | |
| DE102009001438A1 (de) | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel | |
| JP6100755B2 (ja) | （２−ヘテロアリールアミノ）コハク酸誘導体 | |
| CN104119332B (zh) | 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途 |